https://www.nice.org.uk/guidance/ta814
Overview | Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic...
Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis
overviewabrocitinibtralokinumabupadacitinib
https://investingnews.com/news/pharmaceutical-investing/pfizer-announces-extension-of-review-of-new-drug-application-of-abrocitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis/
Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of...
Mar 19, 2024 - Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has extended the priority review period for the New Drug Application...
new drug application